A Phase 2/3 interventional study of Calaspargase pegol (S95015) in Acute Lymphoblastic Leukemia, sponsored by Institut de Recherches Internationales Servier. Terminated at 21 sites in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by Institut de Recherches Internationales Servier · Phase 2/3, Interventional, and Treatment
Sponsor decision.
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,545 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States — 168 open to participants now, 274 under way, 13 of them phase 3. Precursor Cell Lymphoblastic Leukemia-Lymphoma · United States.
Among the 1,545 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States, this one is the 518th largest by enrollment of the 1,269 interventional ones that give a count, is one of 36 that started in 2021, is one of 14 in phase 2/3, and was the 1,325th registered.
2,586 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 471 are open to participants now.
Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →168 of the 1,545 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States are open now. Recruiting first, the newest first:
St. Jude Children's Research Hospital · Sites in United States
Wake Forest University Health Sciences · Sites in United States
Ages 18+
St. Jude Children's Research Hospital · Sites in United States
Ages 8+ · Healthy volunteers
National Cancer Institute (NCI) · Sites in United States
Ages 1–25
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 369 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (70%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.
This study: 22 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,545 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 653 · Phase 2 593 · Phase 3 107 · Phase 4 10
First in 1984; this study’s year is marked. 36 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 42 is close to the median of 40 across 1,953 interventional studies indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Median enrollment 35 across the 1,269 interventional studies, 110 across the 154 observational. Of the 1,181 that completed or were terminated, 438 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
213 of 1,545 have an industry lead sponsor. The 10 most frequent:
Institut de Recherches Internationales Servier is the lead sponsor of 68 studies on the registry; 5 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 9 (50%) have results posted.
Institut de Recherches Internationales Servier has 4 studies filed under Precursor Cell Lymphoblastic Leukemia-Lymphoma — fewer than ten, so there is no comparison to draw.
95 of the studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03020030Phase 3Dana-Farber Cancer InstituteTreatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents | 2026-11-30 |
| NCT03844048Phase 3AbbVieAn Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | 2027-08 |
| NCT04851717Phase 3Acacia Pharma LtdInvestigation of Remimazolam in Children Undergoing Sedation for Medical Procedures | 2027-10 |
| NCT03104491Leland MethenyInotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia | 2026-11 |
| NCT06795126Nationwide Children's HospitalLittle NIRVANA for Pediatric Pain and Anxiety | 2026-11-30 |
Add all 95 to your calendar (.ics) → With an account.
Among the 1,545 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this phase 2/3 study is to confirm the recommended doses and to evaluate the safety and pharmacodynamics of Calaspargase pegol for the treatment of adult patients with Philadelphia-negative Acute Lymphoblastic Leukemia.
The study will be conducted in 2 parts. Part 1 is a dose confirmation run-in period. Part 2 will enroll the remaining participants at the dose as confirmed or recommended in Part 1.
The criteria were revised on the registry on Oct 29, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Calaspargase pegol (S95015)
Part 1: S95015 will be administered at dose of 2000 U/m2, 1500 U/m2 or 1000 U/m2 (dose level based on age and BMI) via a 2-hour intravenous infusion at Day 4 (or 5, or 6) of the induction phase, Days 15 and 43 of the consolidation phase, Day 22 of the interim maintenance phase and Days 4 (or 5, or 6) and 43 of the delayed intensification phase. S95015 starting doses for age and BMI groups will be confirmed. Patients will receive premedication prior to calaspargase pegol administration (acetaminophen, histamine-1 blocker, and corticosteroids to prevent hypersensitivity reaction) and other backbone chemotherapy agents based on the CALGB 10403 protocol treatment regimen. Part 2: Patients aged 22 to 39 years + BMI ≤ 35 kg/m2 will be treated with S95015 1750 U/m2. Patients aged 40 to \< 55 years + BMI ≤ 35 kg/m2 will be treated with S95015 1500 U/m2, unchanged from Part 1. Patients 55 years or older or those with a BMI greater than 35 kg/m2 will no longer be enrolled into Part 2.
Adverse Events (AEs)
Including Treatment-emergent adverse events (TEAEs), adverse events of special interests (AESI); and serious adverse events (SAEs). AEs recorded and evaluated throughout the study in accordance with NCI CTCAE criteria 5.0.
Time frame: Through study completion, approximately 3.5 years
Plasma Asparaginase Activity (PAA) Level (Part 1 and Part 2)
Assessment of PAA in Part 1 is based on population modeling analysis.
Time frame: 7 days, 14 days, 21 days after last administration in the Remission Induction phase (Day 0-35 post baseline) and the Remission Consolidation phase (Day 36-91 post baseline)
Nadir Plasma Asparaginase Activity (NPAA) (Part 2)
Participants with NPAA level ≥0.1 U/mL 21 days after the Remission Consolidation Phase Day 43 dose.
Time frame: Day 64 (Remission Consolidation Phase Day 36-91 post baseline).
Number of Participants With Plasma Asparaginase Activity (PAA) Level ≥0.1 U/mL at Any Time During Remission Induction Phase and Post- Remission Induction Phase, Respectively (Part 1 and Part 2)
Pharmacodynamics criterion.
Time frame: Days 4-5-6&11-18-25 (Induction, Day 0-35 PB (post baseline)); Days 15-16-43-44&22-29-36-50-57-64 (Consolidation, Day 36-91 PB); Days 22-23&29-36-43 (Maintenance, Day 92-147 PB); Days 4-5,43-44 & 11-18-25-50-57-64 (Delayed Intensification, Day 148-203 PB)
Plasma Asparaginase Activity (PAA) Level ≥0.025 U/mL at Predefined Time Points During Remission Induction Phase and Post- Remission Induction Phase, Respectively (Part 1 and Part 2)
Pharmacodynamics criterion.
Time frame: 7 days, 14 days, and 21 days after last administration in the Remission Induction phase (Day 0-35 post baseline) and pre-dose, 7 days, 14 days, and 21 days after last administration in the Remission Consolidation phase (Day 36-91 post baseline)
Plasma Asparaginase Activity (PAA) Level ≥0.1 U/mL at Predefined Time Points During Remission Induction Phase and Post- Remission Induction Phase, Respectively (Part 1 and Part 2)
Pharmacodynamics criterion.
Time frame: 7 days, 14 days, and 21 days after last administration in the Remission Induction phase (Day 0-35 post baseline) and pre-dose, 7 days, 14 days, and 21 days after last administration in the Remission Consolidation phase (Day 36-91 post baseline)
Plasma Asparaginase Activity (PAA) Level ≥0.2 U/mL at Predefined Time Points During Remission Induction Phase and Post- Remission Induction Phase, Respectively (Part 1 and Part 2)
Pharmacodynamics criterion.
Time frame: 7 days, 14 days, and 21 days after last administration in the Remission Induction phase (Day 0-35 post baseline) and pre-dose, 7 days, 14 days, and 21 days after last administration in the Remission Consolidation phase (Day 36-91 post baseline)
Plasma Asparaginase Activity (PAA) Level ≥0.4 U/mL at Predefined Time Points During Remission Induction Phase and Post- Remission Induction Phase, Respectively (Part 1 and Part 2)
Pharmacodynamics criterion.
Time frame: 7 days, 14 days, and 21 days after last administration in the Remission Induction phase (Day 0-35 post baseline) and pre-dose, 7 days, 14 days, and 21 days after last administration in the Remission Consolidation phase (Day 36-91 post baseline)
PAA-derived Maximum Concentration (Cmax) After the Remission Induction Phase Day 4 Dose (Part 1 and 2).
PAA-derived Cmax are based on population modeling analysis.
Time frame: From days 4-25 (Remission Induction, Day 0-35 post baseline)
PAA-derived Area Under the PAA-Time Curve From Time 0 to Day 35 (AUC 0-35) After the Remission Induction Phase Day 4 Dose (Part 1 and 2).
PAA-derived AUC 0-35 are based on population modeling analysis.
Time frame: From Days 0-35 (Remission Induction, Day 0-35 post baseline)
Minimal Residual Disease (MRD) at End of Remission Induction (Part 1 and 2)
Efficacy criterion. A positive result indicates that there is some disease still present. A negative result indicates that there is no disease present.
Time frame: End of remission induction phase (Day 0-35 post baseline) (Day 29).
Participants Who Achieved Complete Remission (CR) (Part 1 and 2)
Morphologic complete remission rate (CR), morphologic complete remission rate with incomplete blood count recovery (CRi).
Time frame: Day 29 remission induction phase (Day 0-35 post baseline)
EFS (Event-free Survival) (Part 1 and 2)
Probability estimates for EFS until 1 year, 2 years, and 3 years
Time frame: Through study completion an average of 3.5 years
DFS (Disease-free Survival) (Part 1 and 2)
Probability estimates for DFS until 1 year, 2 years, and 3 years
Time frame: Through study completion an average of 3.5 years
OS (Overall Survival) (Part 1 and 2)
Probability estimates for OS until 1 year, 2 years, and 3 years
Time frame: Through study completion an average of 3.5 years
Anti-drug (Calaspargase Pegol) Antibody (ADA) Development (Part 1 and 2)
Immunogenicity criterion.
Time frame: Through 365 (±7) days after the first dose or 30 days after the last dose if the participant discontinued
| Milestone | Part 2: Calaspargase Pegol (S95015) 1750 U/m2 | Part 1 and Part 2: Calaspargase Pegol (S95015) 1500 U/m2 | Part 1: Calaspargase Pegol (S95015) 2000 U/m2 | Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (≥ 55 Years) | Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (<55 Years) |
|---|---|---|---|---|---|
| Started | 9 | 11 | 6 | 8 | 8 |
| Completed | 9 | 10 | 5 | 5 | 5 |
| Not completed | 0 | 1 | 1 | 3 | 3 |
| Withdrew: Death | 0 | 1 | 1 | 3 | 2 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 1 |
Including Treatment-emergent adverse events (TEAEs), adverse events of special interests (AESI); and serious adverse events (SAEs). AEs recorded and evaluated throughout the study in accordance with NCI CTCAE criteria 5.0.
| Participants | Part 1: Calaspargase Pegol (S95015) 2000 U/m2 | Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (≥ 55 Years) | Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (<55 Years) | Part 2: Calaspargase Pegol (S95015) 1750 U/m2 | Part 1 and Part 2: Calaspargase Pegol (S95015) 1500 U/m2 |
|---|---|---|---|---|---|
| TEAEs | 6 | 8 | 8 | 9 | 11 |
| AESIs | 4 | 6 | 6 | 7 | 6 |
| SAEs | 2 | 6 | 5 | 8 | 7 |
Assessment of PAA in Part 1 is based on population modeling analysis.
| U/mL | Part 2: Calaspargase Pegol (S95015) 1750 U/m2 | Part 1: Calaspargase Pegol (S95015) 2000 U/m2 | Part 1 and Part 2: Calaspargase Pegol (S95015) 1500 U/m2 | Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (≥ 55 Years) | Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (<55 Years) |
|---|---|---|---|---|---|
| Remission Induction - 7 Days After Last Administration | 0.5911 ± 0.20849 | 0.6487 ± 0.17169 | 0.4121 ± 0.18586 | 0.2398 ± 0.17743 | 0.2523 ± 0.16662 |
| Remission Induction - 14 Days After Last Administration | 0.4182 ± 0.17508 | 0.3711 ± 0.27162 | 0.2651 ± 0.14810 | 0.1487 ± 0.07612 | 0.1550 ± 0.11047 |
| Remission Induction - 21 Days After Last Administration | 0.2894 ± 0.14610 | 0.2702 ± 0.16674 | 0.2097 ± 0.13352 | 0.1093 ± 0.05684 | 0.0573 ± 0.04991 |
| Remission Consolidation - 7 Days After Last Administration | 0.4851 ± 0.33448 | 0.8412 ± 0.42075 | 0.4835 ± 0.26977 | 0.4072 ± 0.15454 | 0.2181 ± 0.22531 |
| Remission Consolidation - 14 Days After Last Administration | 0.4271 ± 0.29779 | 0.5078 ± 0.35939 | 0.3846 ± 0.21038 | 0.2282 ± 0.13321 | 0.1847 ± 0.20467 |
| Remission Consolidation - 21 Days After Last Administration | 0.3318 ± 0.26791 | 0.5445 ± 0.03688 | 0.2664 ± 0.16542 | 0.1567 ± 0.08777 | 0.1125 ± 0.12338 |
Participants with NPAA level ≥0.1 U/mL 21 days after the Remission Consolidation Phase Day 43 dose.
| Participants | Combined: Calaspargase Pegol (S95015) 1750 U/m2 and 1500 U/m2 |
|---|---|
| Nadir Plasma Asparaginase Activity (NPAA) (Part 2) | 5 |
Pharmacodynamics criterion.
| Participants | Part 2: Calaspargase Pegol (S95015) 1750 U/m2 | Part 1 and Part 2: Calaspargase Pegol (S95015) 1500 U/m2 | Part 1: Calaspargase Pegol (S95015) 2000 U/m2 | Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (≥ 55 Years) | Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (<55 Years) |
|---|---|---|---|---|---|
| Number of Participants With Plasma Asparaginase Activity (PAA) Level ≥0.1 U/mL at Any Time During Remission Induction Phase and Post- Remission Induction Phase, Respectively (Part 1 and Part 2) | 9 | 11 | 6 | 8 | 8 |
Pharmacodynamics criterion.
| Participants | Part 2: Calaspargase Pegol (S95015) 1750 U/m2 | Part 1: Calaspargase Pegol (S95015) 2000 U/m2 | Part 1 and Part 2: Calaspargase Pegol (S95015) 1500 U/m2 | Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (≥ 55 Years) | Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (<55 Years) |
|---|---|---|---|---|---|
| Remission Induction - 7 Days After Last Administration | 9 | 6 | 11 | 7 | 7 |
| Remission Induction - 14 Days After Last Administration | 9 | 4 | 11 | 5 | 5 |
| Remission Induction - 21 Days After Last Administration | 9 | 5 | 7 | 5 | 3 |
| Remission Consolidation - Pre-dose | 0 | 4 | 2 | 1 | 0 |
| Remission Consolidation - 7 Days After Last Administration | 3 | 5 | 5 | 5 | 3 |
| Remission Consolidation - 14 Days After Last Administration | 3 | 5 | 4 | 7 | 3 |
| Remission Consolidation - 21 Days After Last Administration | 2 | 4 | 4 | 5 | 2 |
Pharmacodynamics criterion.
| Participants | Part 2: Calaspargase Pegol (S95015) 1750 U/m2 | Part 1: Calaspargase Pegol (S95015) 2000 U/m2 | Part 1 and Part 2: Calaspargase Pegol (S95015) 1500 U/m2 | Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (≥ 55 Years) | Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (<55 Years) |
|---|---|---|---|---|---|
| Remission Induction - 7 Days After Last Administration | 9 | 6 | 11 | 6 | 7 |
| Remission Induction - 14 Days After Last Administration | 9 | 4 | 10 | 5 | 4 |
| Remission Induction - 21 Days After Last Administration | 8 | 5 | 7 | 3 | 2 |
| Remission Consolidation - Pre-Dose | 0 | 1 | 0 | 0 | 0 |
| Remission Consolidation - 7 Days After Last Administration | 3 | 5 | 5 | 5 | 3 |
| Remission Consolidation - 14 Days After Last Administration | 3 | 5 | 4 | 6 | 2 |
| Remission Consolidation - 21 Days After Last Administration | 2 | 4 | 4 | 3 | 2 |
Pharmacodynamics criterion.
| Participants | Part 2: Calaspargase Pegol (S95015) 1750 U/m2 | Part 1: Calaspargase Pegol (S95015) 2000 U/m2 | Part 1 and Part 2: Calaspargase Pegol (S95015) 1500 U/m2 | Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (≥ 55 Years) | Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (<55 Years) |
|---|---|---|---|---|---|
| Remission Induction - 7 Days After Last Administration | 9 | 6 | 10 | 4 | 4 |
| Remission Induction - 14 Days After Last Administration | 8 | 3 | 7 | 2 | 3 |
| Remission Induction - 21 Days After Last Administration | 7 | 4 | 6 | 0 | 0 |
| Remission Consolidation - Pre-Dose | 0 | 0 | 0 | 0 | 0 |
| Remission Consolidation - 7 Days After Last Administration | 3 | 4 | 5 | 5 | 2 |
| Remission Consolidation - 14 Days After Last Administration | 3 | 4 | 4 | 4 | 2 |
| Remission Consolidation - 21 Days After Last Administration | 2 | 4 | 4 | 2 | 2 |
Pharmacodynamics criterion.
| Participants | Part 2: Calaspargase Pegol (S95015) 1750 U/m2 | Part 1: Calaspargase Pegol (S95015) 2000 U/m2 | Part 1 and Part 2: Calaspargase Pegol (S95015) 1500 U/m2 | Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (≥ 55 Years) | Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (<55 Years) |
|---|---|---|---|---|---|
| Remission Induction - 7 Days After Last Administration | 8 | 6 | 4 | 1 | 2 |
| Remission Induction - 14 Days After Last Administration | 4 | 3 | 1 | 0 | 0 |
| Remission Induction - 21 Days After Last Administration | 2 | 2 | 1 | 0 | 0 |
| Remission Consolidation - Pre-Dose | 0 | 0 | 0 | 0 | 0 |
| Remission Consolidation - 7 Days After Last Administration | 3 | 4 | 4 | 2 | 2 |
| Remission Consolidation - 14 Days After Last Administration | 2 | 4 | 3 | 1 | 1 |
| Remission Consolidation - 21 Days After Last Administration | 2 | 4 | 1 | 0 | 0 |
PAA-derived Cmax are based on population modeling analysis.
| IU/L | Part 2: Calaspargase Pegol (S95015) 1750 U/m2 | Part 1 and Part 2: Calaspargase Pegol (S95015) 1500 U/m2 | Part 1: Calaspargase Pegol (S95015) 2000 U/m2 | Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (≥ 55 Years) | Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (<55 Years) |
|---|---|---|---|---|---|
| PAA-derived Maximum Concentration (Cmax) After the Remission Induction Phase Day 4 Dose (Part 1 and 2). | 970.0417 ± 224.09392 | 818.8100 ± 121.41822 | 1043.6224 ± 194.66218 | 579.5235 ± 171.48823 | 580.4971 ± 101.79263 |
PAA-derived AUC 0-35 are based on population modeling analysis.
| IU*hrs/L | Part 2: Calaspargase Pegol (S95015) 1750 U/m2 | Part 1 and Part 2: Calaspargase Pegol (S95015) 1500 U/m2 | Part 1: Calaspargase Pegol (S95015) 2000 U/m2 | Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (≥ 55 Years) | Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (<55 Years) |
|---|---|---|---|---|---|
| PAA-derived Area Under the PAA-Time Curve From Time 0 to Day 35 (AUC 0-35) After the Remission Induction Phase Day 4 Dose (Part 1 and 2). | 306482.6354 ± 102792.09776 | 229404.0145 ± 71993.03662 | 314100.2843 ± 83939.08866 | 145811.0930 ± 65530.10010 | 134979.0088 ± 45507.48622 |
Efficacy criterion. A positive result indicates that there is some disease still present. A negative result indicates that there is no disease present.
| Participants | Part 2: Calaspargase Pegol (S95015) 1750 U/m2 | Part 1 and Part 2: Calaspargase Pegol (S95015) 1500 U/m2 | Part 1: Calaspargase Pegol (S95015) 2000 U/m2 | Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (≥ 55 Years) | Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (<55 Years) |
|---|---|---|---|---|---|
| Positive | 3 | 5 | 3 | 3 | 4 |
| Negative | 3 | 3 | 2 | 1 | 2 |
| Indeterminate | 0 | 0 | 0 | 0 | 0 |
| Not available | 1 | 1 | 0 | 0 | 0 |
| Not performed | 2 | 2 | 1 | 4 | 2 |
Morphologic complete remission rate (CR), morphologic complete remission rate with incomplete blood count recovery (CRi).
| Participants | Part 2: Calaspargase Pegol (S95015) 1750 U/m2 | Part 1 and Part 2: Calaspargase Pegol (S95015) 1500 U/m2 | Part 1: Calaspargase Pegol (S95015) 2000 U/m2 | Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (≥ 55 Years) | Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (<55 Years) |
|---|---|---|---|---|---|
| Participants Who Achieved Complete Remission (CR) (Part 1 and 2) | 6 | 6 | 3 | 5 | 5 |
Probability estimates for EFS until 1 year, 2 years, and 3 years
| Percentage of participants | Part 2: Calaspargase Pegol (S95015) 1750 U/m2 | Part 1 and Part 2: Calaspargase Pegol (S95015) 1500 U/m2 | Part 1: Calaspargase Pegol (S95015) 2000 U/m2 | Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (≥ 55 Years) | Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (<55 Years) |
|---|---|---|---|---|---|
| 1 year | NA (NA to NA) | 27.3 (6.52 to 53.89) | 33.3 (4.61 to 67.56) | 25.0 (3.71 to 55.81) | 12.5 (0.66 to 42.27) |
| 2 years | NA (NA to NA) | 27.3 (6.52 to 53.89) | 33.3 (4.61 to 67.56) | 25.0 (3.71 to 55.81) | 12.5 (0.66 to 42.27) |
| 3 years | NA (NA to NA) | NA (NA to NA) | 33.3 (4.61 to 67.56) | NA (NA to NA) | NA (NA to NA) |
Probability estimates for DFS until 1 year, 2 years, and 3 years
| Percentage of participants | Part 2: Calaspargase Pegol (S95015) 1750 U/m2 | Part 1 and Part 2: Calaspargase Pegol (S95015) 1500 U/m2 | Part 1: Calaspargase Pegol (S95015) 2000 U/m2 | Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (≥ 55 Years) | Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (<55 Years) |
|---|---|---|---|---|---|
| 1 year | NA (NA to NA) | 66.7 (5.41 to 94.52) | 100.00 (100.00 to 100.00) | 75.0 (12.79 to 96.05) | 80.0 (20.38 to 96.92) |
| 2 years | NA (NA to NA) | 66.7 (5.41 to 94.52) | 100.00 (100.00 to 100.00) | 75.0 (12.79 to 96.05) | 80.0 (20.38 to 96.92) |
| 3 years | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Probability estimates for OS until 1 year, 2 years, and 3 years
| Percentage of participants | Part 2: Calaspargase Pegol (S95015) 1750 U/m2 | Part 1 and Part 2: Calaspargase Pegol (S95015) 1500 U/m2 | Part 1: Calaspargase Pegol (S95015) 2000 U/m2 | Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (≥ 55 Years) | Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (<55 Years) |
|---|---|---|---|---|---|
| 1 year | NA (NA to NA) | 85.7 (33.41 to 97.86) | 100.0 (100.00 to 100.00) | 62.5 (22.93 to 86.07) | 75.0 (31.48 to 93.09) |
| 2 years | NA (NA to NA) | 85.7 (33.41 to 97.86) | 100.0 (100.00 to 100.00) | 62.5 (22.93 to 86.07) | 75.0 (31.48 to 93.09) |
| 3 years | NA (NA to NA) | NA (NA to NA) | 83.3 (27.31 to 97.47) | 62.5 (22.93 to 86.07) | 75.0 (31.48 to 93.09) |
Immunogenicity criterion.
| Participants | Part 2: Calaspargase Pegol (S95015) 1750 U/m2 | Part 1 and Part 2: Calaspargase Pegol (S95015) 1500 U/m2 | Part 1: Calaspargase Pegol (S95015) 2000 U/m2 | Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (≥ 55 Years) | Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (<55 Years) |
|---|---|---|---|---|---|
| Negative | 2 | 8 | 5 | 5 | 2 |
| Pre-existing positive | 2 | 1 | 0 | 1 | 1 |
| Treatment-boosted | 2 | 1 | 1 | 0 | 1 |
| Treatment-emergent | 3 | 1 | 0 | 1 | 3 |
Collected over Through study completion, approximately 3.5 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 2: Calaspargase Pegol (S95015) 1750 U/m2 | 0/9 (0%) | 8/9 (88.9%) | 9/9 (100%) |
| Part 1 and Part 2: Calaspargase Pegol (S95015) 1500 U/m2 | 1/11 (9.1%) | 7/11 (63.6%) | 11/11 (100%) |
| Part 1: Calaspargase Pegol (S95015) 2000 U/m2 | 1/6 (16.7%) | 2/6 (33.3%) | 6/6 (100%) |
| Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (≥ 55 Years) | 3/8 (37.5%) | 6/8 (75%) | 8/8 (100%) |
| Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (<55 Years) | 2/8 (25%) | 5/8 (62.5%) | 8/8 (100%) |
| Event | Part 2: Calaspargase Pegol (S95015) 1750 U/m2 | Part 1 and Part 2: Calaspargase Pegol (S95015) 1500 U/m2 | Part 1: Calaspargase Pegol (S95015) 2000 U/m2 | Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (≥ 55 Years) | Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (<55 Years) |
|---|---|---|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 2/9 | 4/11 | 1/6 | 4/8 | 1/8 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/9 | 0/11 | 0/6 | 2/8 | 0/8 |
| HyperbilirubinaemiaHepatobiliary disorders | 0/9 | 0/11 | 0/6 | 2/8 | 0/8 |
| Infusion related hypersensitivity reactionImmune system disorders | 2/9 | 0/11 | 0/6 | 0/8 | 0/8 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 2/9 | 0/11 | 0/6 | 0/8 | 1/8 |
| PyrexiaGeneral disorders | 0/9 | 0/11 | 1/6 | 1/8 | 0/8 |
| AnaemiaBlood and lymphatic system disorders | 0/9 | 0/11 | 0/6 | 1/8 | 0/8 |
| Enterococcal infectionInfections and infestations | 0/9 | 0/11 | 0/6 | 1/8 | 0/8 |
| Pneumonia bacterialInfections and infestations | 0/9 | 0/11 | 0/6 | 1/8 | 0/8 |
| SepsisInfections and infestations | 0/9 | 0/11 | 0/6 | 0/8 | 1/8 |
| Event | Part 2: Calaspargase Pegol (S95015) 1750 U/m2 | Part 1 and Part 2: Calaspargase Pegol (S95015) 1500 U/m2 | Part 1: Calaspargase Pegol (S95015) 2000 U/m2 | Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (≥ 55 Years) | Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (<55 Years) |
|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 5/9 | 5/11 | 5/6 | 5/8 | 2/8 |
| HypoalbuminaemiaMetabolism and nutrition disorders | 2/9 | 4/11 | 4/6 | 1/8 | 2/8 |
| HeadacheNervous system disorders | 4/9 | 7/11 | 3/6 | 1/8 | 3/8 |
| AnaemiaBlood and lymphatic system disorders | 5/9 | 4/11 | 1/6 | 1/8 | 3/8 |
| ConstipationGastrointestinal disorders | 1/9 | 6/11 | 1/6 | 3/8 | 3/8 |
| White blood cell count decreasedInvestigations | 3/9 | 6/11 | 2/6 | 1/8 | 3/8 |
| Blood fibrinogen decreasedInvestigations | 4/9 | 6/11 | 1/6 | 1/8 | 2/8 |
| Oedema peripheralGeneral disorders | 1/9 | 6/11 | 2/6 | 2/8 | 1/8 |
| Alanine aminotransferase increasedInvestigations | 1/9 | 5/11 | 2/6 | 2/8 | 4/8 |
| Blood bilirubin increasedInvestigations | 1/9 | 4/11 | 1/6 | 1/8 | 4/8 |
| Age, Continuous(years) | Part 2: Calaspargase Pegol (S95015) 1750 U/m2 | Part 1 and Part 2: Calaspargase Pegol (S95015) 1500 U/m2 | Part 1: Calaspargase Pegol (S95015) 2000 U/m2 | Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (≥ 55 Years) | Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (<55 Years) | Total |
|---|---|---|---|---|---|---|
| Mean | 25.9 ± 4.17 | 47.5 ± 5.22 | 30.3 ± 3.56 | 64.1 ± 6.85 | 40.1 ± 10.16 | 42.2 ± 14.77 |
| Sex: Female, Male(Participants) | Part 2: Calaspargase Pegol (S95015) 1750 U/m2 | Part 1 and Part 2: Calaspargase Pegol (S95015) 1500 U/m2 | Part 1: Calaspargase Pegol (S95015) 2000 U/m2 | Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (≥ 55 Years) | Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (<55 Years) | Total |
|---|---|---|---|---|---|---|
| Female | 4 | 8 | 2 | 3 | 6 | 23 |
| Male | 5 | 3 | 4 | 5 | 2 | 19 |
| Race/Ethnicity, Customized(Participants) | Part 2: Calaspargase Pegol (S95015) 1750 U/m2 | Part 1 and Part 2: Calaspargase Pegol (S95015) 1500 U/m2 | Part 1: Calaspargase Pegol (S95015) 2000 U/m2 | Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (≥ 55 Years) | Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (<55 Years) | Total |
|---|---|---|---|---|---|---|
| White | 6 | 11 | 4 | 6 | 6 | 33 |
| Black or African American | 2 | 0 | 0 | 0 | 1 | 3 |
| Asian | 0 | 0 | 1 | 1 | 1 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Other | 1 | 0 | 1 | 1 | 0 | 3 |
| Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Part 2: Calaspargase Pegol (S95015) 1750 U/m2 | Part 1 and Part 2: Calaspargase Pegol (S95015) 1500 U/m2 | Part 1: Calaspargase Pegol (S95015) 2000 U/m2 | Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (≥ 55 Years) | Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (<55 Years) | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 4 | 3 | 3 | 1 | 11 |
| Not Hispanic or Latino | 8 | 7 | 3 | 5 | 7 | 30 |
| Not reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown | 1 | 0 | 0 | 0 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified scientific and medical researchers can request access to anonymized patient-level and study-level clinical trial data. Access can be requested for all interventional clinical studies: used for Marketing Authorization (MA) of medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US). where Servier is the Marketing Authorization Holder (MAH). The date of the first MA of the new medicine (or the new indication) in one of the EEA Member States will be considered for this scope. In addition, access can be requested for all interventional clinical studies in patients: sponsored by Servier with a first patient enrolled as of 1 January 2004 onwards for New Chemical Entity or New Biological Entity (new pharmaceutical form excluded) for which development has been terminated before any Marketing authorization (MA) approval.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: After Marketing Authorisation in EEA or US if the study is used for the approval.
Access criteria: Researchers should register on Servier Data Portal and fill in the research proposal form. This form in four parts should be fully documented. The Research Proposal Form will not be reviewed until all mandatory fields are completed.
Data sharing details ↗ · clinicaltrials.servier.com
Ran from Jul 2021 to primary completion in Apr 2025, 44 months.
Results were first posted in Oct 2026, 1 year 6 months after primary completion.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: primary completion Mar 2025 → Apr 2025 and completion Mar 2025 → Apr 2025.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
Sponsor decision.
Sponsor decision.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Calaspargase pegol
Precursor Cell Lymphoblastic Leukemia-Lymphoma →
Institut de Recherches Internationales Servier